SHANGHAI, Jan. 22, 2026 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in a clinical trial in the U.S. of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for the treatment of advanced colorectal cancer and other advanced gastrointestinal tumors.

The Phase I/II study (NCT07216560) represents the first-in-human (FIH) study of 7MW4911 in the United States. The study aims to evaluate the safety, pharmacokinetics and efficacy in patients with advanced colorectal cancer and other advanced gastrointestinal tumors. Previously, 7MW4911 received clinical trial approval and completed first patient dosing in China.

7MW4911 is a novel CDH17-targeting ADC developed by Mabwell based on its proprietary IDDC™ platform. It is composed of a highly specific CDH17 monoclonal antibody capable of efficient internalization into tumor cells, a novel cleavable linker with high plasma stability, and a proprietary DNA topoisomerase I inhibitor payload, MF-6, specifically designed to overcome the multidrug resistance.

Preclinical studies demonstrated that 7MW4911 exhibited potent antitumor activity in CDX/PDX models of various gastrointestinal tumors. In multidrug-resistant models, its antitumor effect was significantly superior to MMAE/DXd-based ADCs, and it was able to reverse tumor progression following treatment with such ADCs, highlighting its advantage in treating resistant tumors. Relevant research findings have been published in the 2025 AACR and the internationally renowned journal Cell Reports Medicine (July 2025).

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from Ideas to Reality.” For more information, please visit www.mabwell.com/en.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

TP is recognized for its customer-centric innovation, operational excellence, and scalable technology that redefine the future of BPO CX outsourcing.

SAN ANTONIO, Jan. 22, 2026 /PRNewswire/ — Based on its recent analysis of the outsourcing market, Frost & Sullivan is recognizing global digital services leader TP for best practices in the global BPO AI industry – Frost’s first recognition in this emerging space. TP has been honored with Frost & Sullivan’s prestigious 2025 Technology Innovation Leadership (TIL). The recognition highlights TP’s innovative AI approach, technology integration, commitment to human capital, and transformative approaches to customer experience and service delivery.

Frost & Sullivan recognizes TP’s development of TP.ai FAB, a proprietary foundational AI backbone platform that transforms and intelligently orchestrates traditional workflows. TP.ai FAB seamlessly integrates AI agents, human Experts, and AI-powered tools to classify, route, and resolve interactions in real time to maximize efficiency and client value. TP’s innovative approach redefines service delivery by combining AI with Emotional Intelligence (EI), ensuring transparency, accountability, and human oversight in AI deployment.

Michael DeSalles, Principal Analyst says, “TP’s focus on human capital is a cornerstone of its success, with a ‘High Tech, High Touch’ philosophy that elevates human expertise through technology.” He continues by adding, “TP.ai FAB empowers human Experts to focus on high-impact tasks, enhances employee well-being, and fosters a culture of innovation and collaboration.”

TP.ai FAB supports a broad and growing portfolio of proprietary and partner-enabled AI products, allowing TP to tailor solutions across industries, geographies, and regulatory contexts. With operations in nearly 100 countries, serving 170 markets in more than 300 languages, TP already delivers live, production-level AI-human collaboration across diverse service environments, positioning TP.ai FAB as a strategic lever for client acquisition, retention, and long-term growth. “TP.ai FAB represents a step-change for TP, and we’re thrilled to receive this TIL recognition, the first of its kind, from Frost & Sullivan,” says Dev Mudaliar, Chief Operating Officer, TP.ai. “We’re excited this helps spotlight the impact TP.ai FAB is already having in helping enterprises of all sizes scale and operationalize AI – delivering successful outcomes across front-, mid-, and back-office environments.”

This recognition underscores TP’s leadership in orchestrating people, process, and technology to redefine customer experiences, drive sustainable growth, and inspire trust and loyalty. TP’s achievement solidifies its position as a global leader in the BPO AI industry, given its ability to deliver transformative solutions that drive cost efficiency and outstanding customer care.

Frost & Sullivan Best Practices recognize companies in various regional and global sectors for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry experts compare sector participants and measure performance through in-depth interviews, analyses, and extensive analysis to identify best practices in the industry.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.

Contact us: Start the discussion.

Contact

CamilaTinajero
E: camila.tinajero@frost.com

About TP

TP is a global leader in digital business services which consistently seeks to blend the best of advanced technology with human empathy to deliver enhanced customer care that is simpler, faster, and safer for the world’s biggest brands and their customers. The Group’s comprehensive, AI-powered service portfolio ranges from front office customer care to back-office functions, including operations consulting and high-value digital transformation services. It also offers a range of specialized services such as collections, interpreting and localization, visa and consular services, and recruitment process outsourcing services. The teams of multilingual, inspired, and passionate experts and advisors, spread in close to 100 countries, as well as the Group’s local presence allows it to be a force of good in supporting communities, clients, and the environment.

CHANGZHOU, China, Jan. 22, 2026 /PRNewswire/ — Jin Medical International Ltd. (NASDAQ: ZJYL) (“Jin Medical”, and together with all its subsidiaries, the “Company”), a NASDAQ-listed leading provider of rehabilitation medical equipment in China, announced today that its wholly-owned subsidiary, Zhongjin Medical Equipment (Anhui) Co., Ltd., has made significant progress in the final construction of its manufacturing facility in Chuzhou, Anhui Province, China. The Company is projected to launch full capacity production by the end of April 2026. The Company completed regulatory filings with the local authorities for the Chuzhou facility on December 29, 2025, and has obtained the license for Class I Medical Device production. The commencement of full production is expected to deliver an annual production capacity of 200,000 units of mid-to-high end electric wheelchairs and senior mobility scooters.

The Chuzhou facility is situated in the heart of the Yangtze River Delta’s manufacturing hub, offering strategic geographical and supply chain advantages. Once fully operational, the project is anticipated to generate a substantial annual output capacity that will significantly enhance Jin Medical’s comprehensive manufacturing capabilities in premium mobility products.

Dr. Erqi Wang, Chairman and CEO of Jin Medical stated, “The completion of this project will support our strategic goal of optimizing global production capacities. The Chuzhou base will strengthen the resilience of our supply chain and accelerate our response to both domestic and international market demands.” According to the Company’s strategic plan, the facility will prioritize production of mid-to-high-end electric wheelchairs and senior mobility scooters during its initial phase, utilizing automated production lines and highly efficient protocols to improve cost control and product quality consistency.

Industry experts note that Jin Medical’s expansion coincides with the growing global demand for assistive devices driven by global aging trend. Located in a region with robust manufacturing infrastructure, the Chuzhou facility is expected to enhance Jin Medical’s market competitiveness through efficient scaled production. The Company reaffirms its commitment to executing the project as planned and creating sustained value for shareholders through efficient execution.

About Jin Medical International Ltd.

Founded in 2006 and headquartered at Changzhou, Jiangsu Province of China, Jin Medical designs, develops, manufactures and markets wheelchairs and living aids products for people with disabilities, elderlies, and for rehabilitation application. Currently, Jin Medical already operates two manufacturing plants of approximately 230,000 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. Jin Medical is currently establishing a new facility with 430,000 square feet in Chuzhou, Anhui Province, China. Jin Medical works with more than 40 distributors in China and more than 20 international distributors. The majority of Jin Medical’s wheelchair products, with more than 30 models, are sold to distributors in Japan and China. Jin Medical continuously delivers innovative wheelchair products that are both lightweight and ergonomic. For more information, please visit: http://www.zhjmedical.com.

Forward-Looking Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may”, “will”, “should”, “intend”, “plan”, “strive”, “believe”, “expect”, “anticipate”, “project”, “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, the Company’s future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, import and export restrictions, fluctuations in general economic and business conditions, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

ir@zhjmedical.com

BEIJING, Jan. 22, 2026 /PRNewswire/ — China’s GDP grew at 5 percent year-on-year to 140.19 trillion yuan ($20.13 trillion) in 2025, data from the National Bureau of Statistics (NBS) showed on Monday, meeting the annual growth target of around 5 percent and surpassing the 140-trillion-yuan threshold for the first time. 

Observers said the upbeat data underscored the resilience and vitality of the world’s second-largest economy despite multiple downward pressures. They added that such growth momentum will continue to position China as a beacon of stability and the locomotive of the world economy. 

While the data represents a resounding success to the conclusion of China’s 14th Five-Year Plan (2021-25) period, it also lays a solid foundation for a head start this year – also the opening year of China’s 15th Five-Year Plan (2026-30), analysts said, noting that China’s economic strength will give the country and the global community greater confidence to navigate an increasingly complex, volatile geopolitical environment and rising waves of trade protectionism in the years to come. 

The economy in the 14th Five-Year Plan period was marked by four consecutive leaps – surpassing 110 trillion yuan, 120 trillion yuan, 130 trillion yuan, and 140 trillion yuan, Kang Yi, head of NBS, said at a press briefing of the State Council Information Office on Monday on the release of the economic data for 2025.

The economy expanded 4.5 percent year-on-year in the fourth quarter last year, data from the NBS showed, easing from 4.8 percent in the third quarter, following 5.2 percent in the second quarter and 5.4 percent in the first quarter.

When asked to comment on China’s economic performance last year, Kang used four keywords: “stable, progressive, innovative, and resilient.” 

“China’s economy has continued to demonstrate strong resilience, navigating instability while achieving both quantitative leaps and qualitative improvements,” said Kang, noting that the country is projected to contribute around 30 percent to global economic growth, serving as a stabilizer for world supply chains.

Yao Jingyuan, a special researcher of the Counselor’s Office of the State Council, told the Global Times on Monday that achieving 5-percent GDP growth and crossing the output milestone of 140 trillion yuan marks the successful completion of the goals listed in the 14th Five-Year Plan (2021-25). Meanwhile, the robust figures have laid a crucial foundation for a strong start to the 15th Five-Year Plan (2026-30) and for resolutely marching toward China’s second centenary goal. 

‘Unprecedented’ challenges

Based on the Global Times’ calculation, the 5-percent increase in China’s GDP also translates to a net growth of 5.38 trillion yuan ($771.73 billion) in economic volume last year, which is more than the entire GDP of Belgium of $671.37 billion in 2024 by World Bank metric. 

Yao said the transcript is by no means easy, as 2025 was an “extraordinary year” during which the internal and external challenges facing the Chinese economy were unprecedented in both scale and intensity.

“Externally, trade protectionism has been on the rise, and de-globalization trends have reemerged. In particular, there have been renewed attempts to contain and suppress China’s development, with the US wielding the tariff stick once again. Internally, China has been dealing with pressures from insufficient demand, an imbalance between supply and demand, as well as the pains associated with economic transformation and upgrading,” Yao said. 

The resilient economic fundamentals, which vividly demonstrated throughout last year’s development trajectory, will provide greater policy maneuver and inspire stronger confidence for a robust start in implementing the 15th Five-Year Plan (2026-2030) in 2026, analysts said.

Tian Yun, a Beijing-based economist, told the Global Times on Monday that the standout developments in new growth drivers last year closely align with the priorities of the 15th Five-Year Plan (2026-30), which places strong emphasis on achieving greater self-reliance and strength in science and technology and steering the development of new quality productive forces.

“So, 2025 served as a critical bridge in deepening this strategic layout,” he added. In the next five years, China is expected to play a greater and more indispensable global role in the face of fragmented global supply chain, intensifying global tech race and rising geopolitical tensions, analysts noted. 

“The resilient and stable growth logged by the Chinese economy has provided a crucial safeguard for the sustainable development of the world economy. On the other hand, China stands today as the world’s most stable supply chain base and the primary production hub for industrial goods. And this position will become more evident in the years to come,” Tian said.

According to Yao, China’s 5-percent growth rate clearly places the country at the forefront among the world’s major economies. An IMF report released on Monday forecasted that global growth will hover around 3.3 percent in 2025. 

The economic expansion of the world’s second-largest economy has also caught the limelight of global mainstream media outlets. A Guardian article cited an economist as saying that “navigating a fraught geopolitical landscape remained a ‘major wildcard,’ but that China’s economy should continue to grow through 2026.” The Associated Press said in a report that China’s economy expanded at a 5 percent annual pace in 2025, buoyed by strong exports despite US tariffs.

Economic highlights

In 2025, China’s value-added industrial output rose by 5.9 percent compared to the same period in 2024, while fixed-asset investment declined by 3.8 percent year-on-year, NBS data showed. China’s retail sales of consumer goods jumped 3.7 percent year-on-year last year.

Hu Qimu, deputy secretary-general of Forum 50 for Digital-Real Economies Integration, highlighted the development of such industries as high-tech and advanced manufacturing, which shows that the development of China’s new quality productive forces has been gearing up and become a prominent driver of the economy in 2025.

Last year, the value added of high-tech manufacturing grew by 9.4 percent year-on-year, outpacing overall growth rate by 3.5 percentage points. The output of industrial robots increased by 28 percent, and new energy vehicles rose by 25.1 percent, data from NBS showed. 

In the fourth quarter, China’s growth in retail sales also stabilized, boosted by a slew of measures that stimulated consumer demand as well as the vibrant spending during the eight-day National Day and Mid-Autumn Festival holidays, analysts said. 

Tian pointed out that the consumer demand has gotten off a good start this year, with notable release of consumer demands during the New Year’s Day holidays, and is expected to continue rising steadily through the upcoming Spring Festival holidays.

Since the beginning of 2026, Chinese authorities have released a bunch of initiatives that aim at spurring consumption and expanding domestic demand, which analysts believe are set to “create favorable conditions for a promising start” in 2026.

“Those are clear signals delivered to the market that the Chinese government will act proactively and front-load its efforts. It is forecasted that more targeted measures will be followed to address persisting economic challenges, which will all help to bolster market confidence and enhance overall social expectation this year,” Hu said. 

A number of economists and global financial institutions are confident on China’s economic prospects.

The IMF report released on Monday has revised the growth forecast for China upward by 0.3 percentage point to 4.5 percent, “reflecting the lower US effective tariff rates on Chinese goods as a result of the yearlong trade truce agreed to in November and stimulus measures that are assumed to be implemented over two years.”

Chinese economy is projected by Goldman Sachs Research to grow by 4.8 percent in 2026 as exports increase and the downward pressure from a slowing property market lessens, according to a report the US investment bank released on its website. 

The country is expected to set its growth target in March at the annual “two sessions.”